Eterna Biologics Ltd
Eterna Biologics is engineering CRISPR technology to develop a new class of RNA-targeting therapeutics. The company combines expertise in RNA biology, CRISPR engineering, and single-cell genomics to advance treatments that modulate gene expression at the RNA level. Their platform leverages proprietary CRISPR systems to address diseases where traditional protein-targeting approaches fall short.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Product
Problem
Many diseases are driven by dysregulated RNA expression or aberrant RNA processing, yet most existing therapeutics target proteins, which limits the range of treatable conditions. RNA-level interventions have the potential to address these diseases, but current tools lack the precision, efficiency, and safety needed for clinical application.
Solution
Eterna Biologics is engineering CRISPR systems to create next-generation RNA-targeting therapeutics. The company harnesses CRISPR technology to precisely bind, cleave, or modulate RNA molecules, enabling therapeutic intervention at the transcript level. Their platform integrates RNA biology, CRISPR engineering, and single-cell genomics to design and validate therapeutic candidates with high specificity. This approach aims to expand the druggable space beyond proteins, offering new treatment options for diseases with unmet medical need.
Target Audience
Primary customers are biotechnology and pharmaceutical companies seeking RNA-targeting therapeutic candidates, as well as academic and clinical research partners focused on RNA-based medicine.
Features
- Proprietary CRISPR-based platform engineered specifically for RNA targeting rather than DNA editing
- Integration of single-cell genomics for high-resolution validation of therapeutic specificity and off-target effects
- Expertise in gene regulatory network research informing target selection and therapeutic design
- RNA-focused therapeutic pipeline addressing conditions not amenable to conventional protein-targeting drugs